Novel viral therapies are emerging and gaining more interest after recent regulatory approval of CAR-T and AAV based gene therapies. While no viral contamination has been reported so far for these therapies, it is important to learn from historical experience and leverage improved manufacturing and testing methods to increase their safety. This would help avoid product supply and patient treatment disruptions as well as protect the company’s business and reputation. In this webinar we will highlight the biosafety challenges associated with the manufacture of viral vectors and how a holistic risk mitigation approach can reduce contamination events.
In this webinar, you will learn:
- Lessons learned from prior contaminations
- How improvements in manufacturing and testing have reduced risk
- How to identify viral safety risk areas